SUIC Worldwide Holdings Ltd. (OTC Markets: SUIC) and VisionRenu Biomedical Technology Co., Ltd. have announced the signing of a Strategic Memorandum of Understanding (MOU) to collaborate in AI-powered biotechnology, precision medicine, and international capital market initiatives. The agreement, disclosed on June 29, 2026, establishes a framework intended to accelerate VisionRenu's global commercialization while creating long-term value through strategic financing and potential access to U.S. capital markets.
Under the MOU, both companies will combine their strengths in medical technology innovation, commercialization, international business development, and capital market access. SUIC, a technology-enabled investment and business acceleration company, will support VisionRenu's expansion efforts, leveraging its expertise in mergers and acquisitions and global market entry. VisionRenu, a Taiwan-based medical technology company specializing in brain health and ophthalmic medical devices, brings its flagship MagRenu® Transcranial Magnetic Stimulation (TMS) System—approved by Taiwan's TFDA for depression treatment—and proprietary ophthalmic laser technologies to the partnership.
The collaboration positions both firms to participate in the rapidly growing AI biotechnology sector. Artificial intelligence is reshaping biotech by accelerating advances in gene editing, DNA synthesis, precision medicine, and digital biology. AI enables faster discovery of disease-related genes, improves CRISPR gene-editing precision, optimizes DNA and protein design, and shortens development cycles for next-generation therapeutics. Combined with automated DNA synthesis and robotic laboratories, AI is transforming biological research through the Design-Build-Test-Learn (DBTL) platform, creating a new era of intelligent life science innovation. Industry analysts expect AI-enabled biotechnology to become one of the world's largest innovation markets over the coming decades, generating multi-trillion-dollar opportunities across healthcare, drug discovery, synthetic biology, advanced manufacturing, and sustainable materials.
Aligned with this global trend, SUIC's strategic collaboration and proposed merger with VisionRenu, together with partnerships involving AI biotechnology startups supported by Taiwan's Ministry of Health and Welfare (MOHW), position the Company to expand into this growing sector. By leveraging AI, precision medicine, gene technologies, and international capital market resources, SUIC aims to accelerate innovation while building long-term shareholder value.
Both companies view the MOU as the first step toward a long-term strategic partnership focused on innovation and sustainable growth. For more information on VisionRenu, visit https://www.vision-renu.com/. Details about SUIC are available at https://sinounitedco.com/.
